Analystreport

Regeneron Pharmaceuticals (REGN) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $800.00 price target on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com